UroGen Pharma reports Q2 EPS (91c), consensus (83c)
PremiumThe FlyUroGen Pharma reports Q2 EPS (91c), consensus (83c)
1M ago
Is URGN a Buy, Before Earnings?
Premium
Pre-Earnings
Is URGN a Buy, Before Earnings?
1M ago
UroGen Pharma Shareholders Shape Governance and Incentives
Premium
Company Announcements
UroGen Pharma Shareholders Shape Governance and Incentives
1M ago
UroGen Pharma price target raised to $40 from $32 at Oppenheimer
PremiumThe FlyUroGen Pharma price target raised to $40 from $32 at Oppenheimer
3M ago
UroGen Pharma price target raised to $53.50 from $48 at Ladenburg
Premium
The Fly
UroGen Pharma price target raised to $53.50 from $48 at Ladenburg
3M ago
UroGen Pharma price target raised to $60 from $54 at H.C. Wainwright
Premium
The Fly
UroGen Pharma price target raised to $60 from $54 at H.C. Wainwright
3M ago
UroGen Pharma trading halted, news pending
PremiumThe FlyUroGen Pharma trading halted, news pending
3M ago
UroGen Pharma announces David Lin as chief commercial officer
Premium
The Fly
UroGen Pharma announces David Lin as chief commercial officer
4M ago
UroGen Pharma price target lowered to $32 from $34 at Oppenheimer
Premium
The Fly
UroGen Pharma price target lowered to $32 from $34 at Oppenheimer
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100